Variable | Enterobacter SBP (n = 32) | E. coli SBP (n = 128) | P |
---|---|---|---|
Initial empirical antimicrobial agent | |||
 Cefotaxime | 27 (84.4) | 116 (90.6) | 0.31 |
 Imipenem or meropenem | 4 (12.4) | 9 (7.0) |  |
 Cefazolin | 1 (3.1) | 0 (0) |  |
 Ceftazidime | 0 (0) | 1 (0.8) |  |
 Cefepime | 0 (0) | 1 (0.8) |  |
 Levofloxacin | 0 (0) | 1 (0.8) |  |
Appropriateness of initial therapy | 27 (87.1) | 109 (87.2) | 1.00 |
Initial response to empirical treatmenta | 26/32 (81.3) | 95/117 (81.2) | 0.995 |
Emergence of resistance during third-generation cephalosporin treatment | 1/23 (4.3) | 0/98 (0) | 0.19 |
Duration of hospitalization, median days (IQR) | |||
 Overall | 20 (11–31) | 16 (10–26) | 0.28 |
 Survivors | 22 (12–31) | 16 (11–26) | 0.41 |
Duration of antimicrobial use, median days (IQR) | |||
 Overall | 15 (11–25) | 13 (8–16) | 0.02 |
 Survivors | 16 (13–29) | 13 (10–16) | 0.01 |
ICU care during admission | 2 (6.2) | 19 (14.8) | 0.25 |
Mortality | |||
 14-day mortality | 7 (21.9) | 25 (19.5) | 0.77 |
 30-day mortality | 12 (37.5) | 37 (28.9) | 0.35 |
 In-hospital mortality | 12 (37.5) | 28 (21.9) | 0.07 |